<p>Dr Reddy's Laboratories on Tuesday said it has inked a licensing pact with Eli Lilly and Company to produce Baricitinib in the country for treatment of Covid-19.</p>.<p>The Hyderabad-based firm said it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company for the manufacture and commercialisation of the drug in India.</p>.<p>Baricitinib has received restricted emergency use approval from the Central Drugs Standard Control Organisation (CDSCO) for use in combination with remdesivir for the treatment of suspected or laboratory-confirmed Covid-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).</p>.<p><strong>Also Read | <a href="http://Eli Lilly inks pacts with Sun Pharma, Cipla, Lupin for Covid-19 treatment drug Read more at: https://www.deccanherald.com/business/business-news/eli-lilly-inks-pacts-with-sun-pharma-cipla-lupin-for-covid-19-treatment-drug-984392.html" target="_blank">Eli Lilly inks pacts with Sun Pharma, Cipla, Lupin for Covid-19 treatment drug</a></strong></p>.<p>This partnership comes at a critical juncture in the fight against the pandemic in India, and adds to the company's existing range of Covid-19 therapeutics covering the full spectrum from mild to moderate and severe conditions of the disease, and a vaccine, Dr Reddy's noted.</p>.<p>"From the start, we have been determined to explore every possible avenue against Covid-19. Our collaboration with Lilly will help us make yet another treatment option available to patients in India," Dr Reddy's Laboratories CEO (API and Services) Deepak Sapra said.</p>.<p>On May 10, Eli Lilly and Company had announced voluntary licensing agreements with Sun Pharma, Cipla and Lupin to expedite availability of its arthritis drug Baricitinib for treatment of Covid-19 patients in India</p>
<p>Dr Reddy's Laboratories on Tuesday said it has inked a licensing pact with Eli Lilly and Company to produce Baricitinib in the country for treatment of Covid-19.</p>.<p>The Hyderabad-based firm said it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company for the manufacture and commercialisation of the drug in India.</p>.<p>Baricitinib has received restricted emergency use approval from the Central Drugs Standard Control Organisation (CDSCO) for use in combination with remdesivir for the treatment of suspected or laboratory-confirmed Covid-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).</p>.<p><strong>Also Read | <a href="http://Eli Lilly inks pacts with Sun Pharma, Cipla, Lupin for Covid-19 treatment drug Read more at: https://www.deccanherald.com/business/business-news/eli-lilly-inks-pacts-with-sun-pharma-cipla-lupin-for-covid-19-treatment-drug-984392.html" target="_blank">Eli Lilly inks pacts with Sun Pharma, Cipla, Lupin for Covid-19 treatment drug</a></strong></p>.<p>This partnership comes at a critical juncture in the fight against the pandemic in India, and adds to the company's existing range of Covid-19 therapeutics covering the full spectrum from mild to moderate and severe conditions of the disease, and a vaccine, Dr Reddy's noted.</p>.<p>"From the start, we have been determined to explore every possible avenue against Covid-19. Our collaboration with Lilly will help us make yet another treatment option available to patients in India," Dr Reddy's Laboratories CEO (API and Services) Deepak Sapra said.</p>.<p>On May 10, Eli Lilly and Company had announced voluntary licensing agreements with Sun Pharma, Cipla and Lupin to expedite availability of its arthritis drug Baricitinib for treatment of Covid-19 patients in India</p>